NCT07714902 Administration Of Calcium Gluconate for The Reduction of Blood Loss During Vaginal Delivery
| NCT ID | NCT07714902 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rambam Health Care Campus |
| Condition | Postpartum Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 710 participants |
| Start Date | 2026-06-24 |
| Primary Completion | 2027-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 710 participants in total. It began in 2026-06-24 with a primary completion date of 2027-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Postpartum hemorrhage is one of the leading causes of maternal morbidity following childbirth. Even when excessive bleeding is not clinically recognized, some women experience a significant decrease in hemoglobin levels after delivery, which may result in anemia, fatigue, delayed recovery, and the need for additional medical treatment. Calcium plays an important role in uterine muscle contraction and blood clotting. Previous studies have suggested that calcium administration may help reduce blood loss after childbirth. However, there is limited evidence regarding its effectiveness during vaginal delivery. The purpose of this study is to evaluate whether administration of intravenous calcium gluconate immediately after umbilical cord clamping can reduce postpartum blood loss following vaginal delivery. Participants will be randomly assigned to receive either calcium gluconate or a placebo solution immediately after umbilical cord clamping during vaginal delivery. Neither the participants nor their healthcare providers will know which treatment was administered. Blood tests routinely obtained during hospitalization after delivery will be used to assess changes in hemoglobin levels and other outcomes related to postpartum bleeding. The results of this study may help determine whether calcium gluconate is a safe and effective intervention for reducing postpartum blood loss after vaginal delivery.
Eligibility Criteria
Inclusion Criteria: * Gestational age of 37 weeks or more, and planning a vaginal delivery. Exclusion Criteria: * Age younger than 18 years old. * Patients treated with calcium channel blockers * Patients with Preeclampsia with severe features receiving magnesium sulfate infusion. * Chronic renal failure and hyperphosphatemia * Patients with known Para-Thyroid disease * Sarcoidosis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07714902 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Postpartum Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07714902 currently recruiting?
Yes, NCT07714902 is actively recruiting participants. Contact the research team at gili.buchnik@gmail.com for enrollment information.
Where is the NCT07714902 trial being conducted?
This trial is being conducted at Haifa, Israel.
Who is sponsoring the NCT07714902 clinical trial?
NCT07714902 is sponsored by Rambam Health Care Campus. The trial plans to enroll 710 participants.